share_log

Tonix Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q:2024財年二季報
美股SEC公告 ·  08/16 17:23

Moomoo AI 已提取核心訊息

Tonix Pharmaceuticals Holding Corp. (Tonix) reported financial results for the quarter ended June 30, 2024. The company recognized revenue of $2.2 million, primarily from the sale of two marketed products, Zembrace SymTouch and Tosymra, acquired in July 2023. Cost of sales was $3.4 million, including inventory write-downs of approximately $1.7 million. Research and development expenses decreased by 56% to $9.7 million, due to reduced clinical, non-clinical, and manufacturing expenses. General and administrative expenses increased by 7% to $7.5 million, attributed to higher financial reporting and sales and marketing costs. The company recorded a non-cash impairment charge of $58.9 million related to property, equipment, goodwill, and intangible assets. The net loss for the quarter was $78.8 million, a 177% increase from the previous year's $28.4 million. Tonix's cash resources are...Show More
Tonix Pharmaceuticals Holding Corp. (Tonix) reported financial results for the quarter ended June 30, 2024. The company recognized revenue of $2.2 million, primarily from the sale of two marketed products, Zembrace SymTouch and Tosymra, acquired in July 2023. Cost of sales was $3.4 million, including inventory write-downs of approximately $1.7 million. Research and development expenses decreased by 56% to $9.7 million, due to reduced clinical, non-clinical, and manufacturing expenses. General and administrative expenses increased by 7% to $7.5 million, attributed to higher financial reporting and sales and marketing costs. The company recorded a non-cash impairment charge of $58.9 million related to property, equipment, goodwill, and intangible assets. The net loss for the quarter was $78.8 million, a 177% increase from the previous year's $28.4 million. Tonix's cash resources are expected to fund operations into the third quarter of 2024, but not beyond. The company continues to seek additional funding and may need to scale back or eliminate some operations if additional funds are not secured. Tonix's stock is at risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement. The company's future capital requirements will depend on various factors, including research and development progress, regulatory outcomes, and the ability to develop markets for its product candidates.
Tonix Pharmaceuticals控股公司(Tonix)報告了2024年6月30日結束的季度的財務業績。公司主要通過銷售兩種在2023年7月收購的市場產品Zembrace SymTouch和Tosymra,實現了220萬美元的營業收入。銷售成本爲340萬美元,其中包括約170萬美元的庫存減值。由於減少了臨床、非臨床和製造方面的開支,研發費用減少了56%至970萬美元。總部和行政費用增長了7%至750萬美元,歸因於更高的財務報告和銷售與營銷成本。公司記錄了一筆5890萬美元的非現金減值損失,相關資產包括財產、設備、商譽和無形資產。本季度淨虧損爲7,880萬美元,比去年同期增長177%的2...展開全部
Tonix Pharmaceuticals控股公司(Tonix)報告了2024年6月30日結束的季度的財務業績。公司主要通過銷售兩種在2023年7月收購的市場產品Zembrace SymTouch和Tosymra,實現了220萬美元的營業收入。銷售成本爲340萬美元,其中包括約170萬美元的庫存減值。由於減少了臨床、非臨床和製造方面的開支,研發費用減少了56%至970萬美元。總部和行政費用增長了7%至750萬美元,歸因於更高的財務報告和銷售與營銷成本。公司記錄了一筆5890萬美元的非現金減值損失,相關資產包括財產、設備、商譽和無形資產。本季度淨虧損爲7,880萬美元,比去年同期增長177%的2,840萬美元。儘管Tonix公司的現金資源預計可支持運營至2024年第三季度,但無法支持更長時間。如果無法獲得額外資金,該公司將繼續尋求額外的融資,並可能需要縮減或取消一些運營。Tonix公司的股票面臨被Nasdaq除牌的風險,因爲未能符合最低標價要求。該公司未來的資本需求將取決於各種因素,包括研發進展、監管結果以及發展其產品候選者市場的能力。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息